FinscoFinsco

Harmony Biosciences (US.HRMY)

Capital Allocation Audit · Period: 2018 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.HRMY · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.0%→
ROE3.6%↓
Cash Conversion85.4%↑
D/E Ratio0.17↑
Gross Margin79.3%→
US.HRMY (Harmony Biosciences) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE                3.6%    ↓
Cash Conversion   85.4%    ↑
D/E Ratio          0.17    ↑
Gross Margin      79.3%    →
Key Metrics
US.HRMY (Harmony Biosciences) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE 3.6% ↓
Cash Conversion 85.4% ↑
D/E Ratio 0.17 ↑
Gross Margin 79.3% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies